Karyopharm Therapeutics
Newton
About Karyopharm Therapeutics
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFºB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $637.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:KPTI
- Website: karyopharm.com
- Phone: +1 617 658 0600
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/karyopharm-therapeutics-67946 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.